• Genetic determinants of response to clopidogrel and cardiovascular events. Simon T et al. N Engl J Med. 2009 Jan 22;360(4):363-75.
  • Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Varenhorst C et al. Eur Heart J. 2009 Jul;30(14):1744-52.
  • CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients-Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. Bergmeijer TO et al. Am Heart J. 2014 Jul;168(1):16-22.
  • 2014/EACTS Guidelines on myocardial revascularization. Windecker S et al. European Heart Journal doi:10.1093/eurheartj/ehu278.